Bausch + Lomb Corporation (BLCO) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate a positive outlook. The company raised its revenue and EBITDA guidance, showing confidence in future performance. Despite a gross margin decline, there's an expected sequential improvement. The enVista platform recovery and strategic investments in growth areas like the dry eye market and contact lens portfolio are promising. The Q&A highlighted strong management strategies in financial excellence and market growth. While there were some uncertainties, such as tariff impacts, the overall sentiment is positive, suggesting a stock price increase of 2% to 8%.
Key Financial Performance
Total company revenue $1.281 billion, reflecting year-over-year growth of 6%. Revenue growth was across all segments, with currency being a tailwind of approximately $19 million.
Vision Care revenue $736 million, increased by 6% year-over-year. Growth driven by consumer and contact lenses, despite a destocking impact of approximately $6 million.
Consumer business growth 6% in Q3. Eye vitamins grew by 11%, LUMIFY generated $48 million in revenue (up 2%), and the consumer dry eye portfolio delivered $113 million in revenue (up 18%).
Contact lens revenue Grew by 6%. Daily SiHy was up 24%, Biotrue up 7%, and Ultra up 4%. U.S. market grew by 9%, and international market grew by 4%.
Surgical segment revenue $215 million, an increase of 1%. Excluding the enVista recall, revenue growth was 7%. Implantables were up 2% and 14% sequentially, consumables were flat on a constant currency basis, and equipment was up 4%.
Pharma segment revenue $330 million, an increase of 7%. U.S. branded Rx business was up 13%. Miebo delivered $84 million in revenue (71% increase year-over-year), and Xiidra delivered $87 million in revenue (TRx growth of 8%).
Adjusted gross margin 61.7%, representing a 130 basis points decrease year-over-year, mainly driven by product mix and the onetime impact of the enVista recall.
Adjusted R&D investment $95 million in Q3, representing an increase of approximately 13% over Q3 of 2024.
Adjusted EBITDA $243 million, up 7% year-over-year on a reported basis. Adjusted EBITDA margin was 19%, representing a sequential increase of 400 basis points.
Adjusted cash flow from operations $161 million in Q3, and adjusted free cash flow was $87 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Miebo Revenue: Generated $84 million in Q3, bolstering the dry eye portfolio.
enVista Intraocular Lenses: Achieved 27% constant currency revenue growth in premium IOLs.
Pipeline Products: Includes new formulations of LUMIFY, PreserVision, and Blink Triple Care, next-gen lifitegrast for dry eye disease, ocular surface pain medication, glaucoma medication, and a bioactive contact lens.
Daily SiHy Contact Lenses: Expanded portfolio with 24% constant currency revenue growth in Q3.
Daily SiHy Portfolio Expansion: Launched a toric model in Japan, now in over 50 countries.
Artelac Expansion: Available in more than 40 countries with plans for further expansion.
Revenue Growth: Total company revenue grew 6% year-over-year to $1.281 billion in Q3.
Adjusted EBITDA: Increased 7% year-over-year to $243 million in Q3.
Cash Flow: Adjusted cash flow from operations was $161 million in Q3.
Margin Expansion: Adjusted EBITDA margin increased by 400 basis points sequentially to 19%.
Financial Excellence: Introduced as a new category to deliver sustained profitable growth.
Innovation Focus: Pipeline filled with disruptive products aimed at elevating eye health standards.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Destocking Impact: The company absorbed a destocking impact of approximately $6 million in Q3, which could indicate challenges in inventory management or demand forecasting.
Adjusted Gross Margin Decline: Adjusted gross margin for Q3 decreased by 130 basis points year-over-year, driven by product mix and the onetime impact of the enVista recall, which could affect profitability.
EnVista Recall: The enVista recall has impacted revenue growth in the Surgical segment, although recovery efforts are underway. This poses a risk to regaining full market momentum.
Tariff Policy Uncertainty: The fluidity of tariff policies could impact the company's cost structure and profitability, although current guidance assumes the impact will be offset.
Competitive Pressures in Dry Eye Treatment: The entry of a new competitor in the dry eye disease treatment market could challenge the growth trajectory of key products like Miebo and Xiidra.
Inventory Work-Down in Consumer Segment: A work-down of inventory in the consumer segment could indicate potential challenges in demand or supply chain management.
R&D Investment Increase: The company invested $95 million in adjusted R&D in Q3, a 13% increase year-over-year, which could strain short-term financials despite its long-term potential.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: Maintaining full-year revenue guidance at a range of $5.05 billion to $5.15 billion, representing constant currency growth of approximately 5% to 7%.
Adjusted EBITDA Guidance for 2025: Updated to a range of $870 million to $910 million, raising the lower end of the range due to strong business performance.
Adjusted Gross Margin: Expected to be approximately 61.5% for the full year.
R&D Investments: Expected to be approximately 7.5% of revenue for the full year.
Interest Expense: Expected to be approximately $375 million for the full year.
Adjusted Tax Rate: Expected to be approximately 15% for the full year.
Capital Expenditures: Expected to be approximately $295 million for the full year.
Tariff Impact: Assumes the impact of tariffs in 2025 will be offset based on current policy and actions.
Pipeline and Product Launches: Anticipated launches of clinical-stage programs over the next several years, including new formulations of LUMIFY, PreserVision, and Blink Triple Care, next-generation lifitegrast for dry eye disease, ocular surface pain medication, glaucoma medication, and a bioactive contact lens.
Daily SiHy Portfolio Expansion: Continued expansion with new offerings under development, including a cost-competitive daily disposable, a frequent replacement offering, and a lens designed to slow myopia progression in children and adolescents.
PreserVision New Formulation: Expected to be on shelves in the first half of 2026, potentially increasing the addressable market for age-related macular degeneration.
EnVista IOL Platform Recovery: Faster-than-expected recovery with total enVista sales in Q3 reaching 82% of pre-recall levels and Envy sales at 91%.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the purpose of the newly added financial excellence pillar?
A:The financial excellence pillar is about sharpening day-to-day execution, ensuring every dollar spent drives growth and/or efficiency. It focuses on controlling operating expenses, improving mix, and setting up for meaningful margin expansion over time. It is not just about cost-cutting but disciplined execution and better resource allocation.
Q:What is the company's performance in the contact lens market?
A:The company has been growing faster than the market, which is growing in the mid-single digits. This growth is attributed to new product innovations and good execution. The company avoids the 'leaky bucket syndrome' by growing new products while maintaining growth in older products.
Q:What is the company's strategy for the dry eye market, particularly with Miebo and Xiidra?
A:The company sees the dry eye market as multifactorial and believes in the potential of combination therapy to address the disease. Miebo is the only product approved for evaporative dry eye, and the company is confident in its profile. They are targeting new programs combining Miebo and Xiidra to enhance efficacy, compliance, and reduce adverse events.
Q:What is the status of the surgical business post-recall?
A:The enVista platform has shown impressive recovery, with metrics indicating strong sequential and year-over-year growth. The company is quickly approaching pre-recall revenue levels, with some brands surpassing those levels. The recall is nearly behind them, and they are focusing on growth.
Q:How is the company balancing SG&A leverage and reinvestment for growth?
A:The company aims to make SG&A improvements sustainable while prioritizing investments in R&D and growth opportunities. They are reallocating SG&A dollars towards revenue generation and maintaining a balance between cost discipline and reinvestment in the business.
Q:What is the company's approach to tariffs and their impact?
A:The company is managing tariffs through mitigation strategies and remains on solid ground despite the fluid situation. They are monitoring developments, such as trade negotiations, and have a dedicated team to address tariff impacts.
Q:What is the company's outlook for the contact lens market?
A:The market is expected to grow in the mid-single digits, with some softness in regions like Southeast Asia and China. The company is monitoring consumer behavior and expects to grow faster than the market, focusing on the premium segment.
Q:What are the factors affecting gross profit margin this quarter?
A:The gross margin declined by 130 basis points year-over-year due to product mix and the ramp-up of the enVista reintroduction. Sequential improvement is expected in the next quarter due to enVista's recovery and seasonality.
Q:What is the company's capital allocation strategy?
A:The company prioritizes deleveraging to achieve investment-grade status, investing in the business for growth, and increasing shareholder value. They are focused on maintaining a balance between debt reduction and strategic investments.
Q:What is the company's perspective on the dry eye market growth and investments?
A:The dry eye market is growing at around 10% annually, with a long runway for growth. The company plans to continue investing in Miebo and Xiidra while being prudent and focusing on high ROI opportunities.
Q:What is the company's approach to the U.S. generics business?
A:The U.S. generics business is viewed as opportunistic, focusing on profitability and market disruptions. The company uses it to create absorption in their U.S. plant and generate good margins when opportunities arise.
Q:What is the profitability outlook for Miebo?
A:Miebo's profitability is expected to align with the company's 2026 guidance. Investments in the product are transitioning from launch phase to growth phase, with a focus on high ROI opportunities.
Q:What is the company's approach to Miebo's ASP fluctuations?
A:Miebo's ASP is influenced by gross-to-net adjustments, which are around mid-70s on an annual basis. Quarterly fluctuations are less indicative, and the company focuses on annual trends.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about the gross tariff impact for 2026, citing the fluidity of the situation and ongoing trade negotiations. They also did not provide specific details on the magnitude of the tariff impact for next year.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO category
Care category
Care contact
Consumables currency
Daily Biotrue
Daily offering
Day performer
Day plan
Day product
Day sneak
Eye vitamin
Gadkowski Vice
IOLs Consumables
IOLs display
IP RD
Insights presentation
Investor Day
LUMIFY consumption
Miebo eye
Miebo increase
Mr Saunders
Pharmaceuticals standout
PreserVision
RD increase
cash flow
category excellence
cost
expectation
generation
generic
implantables
margin expansion
medication
patient consumer
professional patient
recall
science
tariff
update
BLCO Transcript
Bausch + Lomb Corporation (BLCO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-9
Bausch + Lomb Corporation (BLCO) Q1 2026 Earnings Call Transcript
Positive4-29
The earnings call highlights strong financial performance with a 5% revenue increase, improved gross margin, and a 15% rise in net income and EPS. These metrics indicate operational efficiency and growth potential. However, the lack of discussion on strategic initiatives and risks might limit the overall sentiment. Despite this, the positive financial results and optimistic guidance for the year support a positive sentiment, likely leading to a 2% to 8% stock price increase over the next two weeks.
Bausch + Lomb Corporation (BLCO) Q4 2025 Earnings Call Transcript
Positive2-18
The company demonstrated strong financial performance and optimistic guidance, with record high revenue and EBITDA, and a strategic focus on high-margin products and disciplined execution. New product launches and improvements in EBITDA margins are planned. Despite some concerns about limited float, the company is committed to resolving it. The Q&A highlighted confidence in market positioning and growth strategies, further supporting a positive outlook. Overall, these factors suggest a likely positive stock price movement over the next two weeks.
Bausch + Lomb Corporation (BLCO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
BLCO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
